Nausea is typically most prominent during the first few weeks of treatment and following dose increases, but usually improves over time as the body adapts
These mothers often benefit most from GLP-1 therapy because their appetite and glucose systems remain dysregulated longer
Lab work typically checks metabolic markers, thyroid function, and kidney function, all of which are relevant when starting GLP-1 therapy
The presence of multiple smaller peaks indicates impurities, which could be truncated sequences, non-target modifications from synthesis, or residual reagents
Clinical trials did not identify changes in sexual function as a significant adverse event associated with liraglutide treatment
Further studies exploring these aspects are needed